Publications by authors named "P Anthopoulos"
Objective: To determine the prognostic impact of coronary artery disease (CAD) in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).
Background: CAD is a common comorbidity among patients undergoing TAVR and studies provide conflicting data on its prognostic impact.
Methods: The Bivalirudin on Aortic Valve Intervention Outcomes-3 (BRAVO-3) randomized trial compared the use of bivalirudin versus UFH in 802 high-surgical risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis.
Article Synopsis
- Recruitment rates for Crohn's disease and ulcerative colitis clinical trials are decreasing, impacting access to new treatments for patients with inflammatory bowel disease (IBD).
- The study identifies challenges affecting recruitment and suggests solutions like being more patient-centric, using less appealing placebo formats, and reducing patient burden through innovative methods.
- Conclusions emphasize the need for the IBD community to tackle various issues in trial conduct to enhance recruitment and ensure patients gain access to essential therapies.
Article Synopsis
- The study aimed to assess the effect of anemia on outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) using either bivalirudin or unfractionated heparin (UFH).
- The BRAVO-3 trial involved 802 high-risk patients and analyzed complications within 30 days after the procedure, focusing on net adverse cardiac events and major bleeding.
- Results indicated that while anemia did not increase the risk of major bleeding or adverse cardiac events regardless of the anticoagulant used, anemic patients had a significantly higher risk of major vascular complications and acute kidney injury.
Background: Acute kidney injury (AKI) is not uncommon in patients undergoing transcatheter aortic valve replacement (TAVR).
Objective: We examined the incidence, predictors, and outcomes of AKI from the BRAVO 3 randomized trial.
Methods: The BRAVO-3 trial included 802 patients undergoing transfemoral TAVR randomized to bivalirudin vs.
Background/objectives: Clinicians use validated scores to risk-stratify patients undergoing transcatheter aortic valve replacement (TAVR). However, evaluation by the Heart Team often deems patients to be at higher risk than their formal scores suggest. We sought to assess clinical outcomes of TAVR patients defined as high-risk by the Heart Team's assessment versus the patient's logistic EuroSCORE (LES).
View Article and Find Full Text PDF